Staging of the Axilla in Breast Cancer and the Evolving Role of Axillary Ultrasound
Open Access
- 1 May 2021
- journal article
- review article
- Published by Taylor & Francis in Breast Cancer: Targets and Therapy
- Vol. ume 13, 311-323
Abstract
Axillary lymph nodes have long been recognized as a route for breast cancer to spread systemically. As a result, staging of the axilla has always played a central role in the treatment of breast cancer. Anatomic staging was believed to be important for two reasons: 1) it predicts prognosis and guides medical therapy, and 2) it is a potential therapy for removal of disease in the axilla. This paradigm has now been called into question. Prognostic information is driven increasingly by tumor biology, and trials such as the ACOSOG Z0011 demonstrates removal of axillary disease is not therapeutic. Staging of the axilla has undergone a dramatic de-escalation; however, sentinel lymph node biopsy (SLNB) is still an invasive surgery and represents a large economic burden on the healthcare system. In this review, we outline the changing paradigms of axillary staging in breast cancer from emphasis on anatomic staging to tumor biology, and the evolving role of axillary ultrasound, bringing patients less invasive and more personalized therapy.Keywords
This publication has 84 references indexed in Scilit:
- Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy in Patients With Node-Positive Breast CancerJAMA, 2013
- Preoperative Ultrasound-Guided Needle Biopsy of Axillary Nodes in Invasive Breast CancerAnnals of Surgery, 2011
- Axillary Dissection vs No Axillary Dissection in Women With Invasive Breast Cancer and Sentinel Node MetastasisJAMA, 2011
- Distant metastasis occurs late during the genetic evolution of pancreatic cancerNature, 2010
- Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trialThe Lancet Oncology, 2010
- Morbidity results from the NSABP B‐32 trial comparing sentinel lymph node dissection versus axillary dissectionJournal of Surgical Oncology, 2010
- Sentinel-lymph-node biopsy as a staging procedure in breast cancer: update of a randomised controlled studyThe Lancet Oncology, 2006
- Randomized Multicenter Trial of Sentinel Node Biopsy Versus Standard Axillary Treatment in Operable Breast Cancer: The ALMANAC TrialJNCI: Journal of the National Cancer Institute, 2006
- Lymphatic mapping and sentinel lymph node biopsy in early‐stage breast carcinomaCancer, 2005
- Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implicationsProceedings of the National Academy of Sciences of the United States of America, 2001